ArticleAmerican heart journal2025
Rationale and design of the PE-TRACT trial: A multicenter randomized trial to evaluate catheter-directed therapy for the treatment of intermediate-risk pulmonary embolism.
Article in American heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05591118 (Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Catheter-Directed Mechanical Thrombectomy without Thrombolysis for Intermediate-to-High-Risk Acute Pulmonary Embolism: A Systematic Review and Meta-Analysis.Cardiovascular and interventional radiology · 2026Pooled it
- The 2026 pulmonary embolism guideline in a regional intensive care unit: Reading the recommendations without a catheter laboratory.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2026Article
- Safety profile and resource utilisation associated with systemic alteplase versus unfractionated heparin in intermediate-high risk pulmonary embolism: a prospective ICU cohort study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Editorial regarding 2026 American Heart Association/American College of Cardiology/American College of Clinical Pharmacy/American College of Emergency Physicians/American College of Chest Physicians/Society for Cardiovascular Angiography and Interventions/Society of Hospital Medicine/Society of Interventional Radiology/Society for Vascular Medicine/Society for Vascular Nursing guideline for the evaluation and management of acute pulmonary embolism in adults.Journal of vascular surgery. Venous and lymphatic disorders · 2026Article
- Initial management of intermediate- and high-risk pulmonary embolism.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Review
- Trends and Therapeutic Imperatives in Pulmonary Embolism Therapy.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Long-Term Outcomes After Catheter-Directed Thrombolysis or Mechanical Thrombectomy in Intermediate-High-Risk Pulmonary Embolism: A Propensity-Matched Analysis From a TriNetX Database.Pulmonary circulation · 2026Article
- Contemporary Challenges in Venous Thromboembolism: Evolving Populations and Implications for Management and Risk Stratification.Journal of clinical medicine · 2026Review
- Ultrasound-facilitated Catheter-directed Thrombolysis in Intermediate- to High-risk Pulmonary Embolism: Perspectives on the HI-PEITHO Trial.US cardiology · 2026Review
- Mortality in patients undergoing catheter-based therapy vs. anticoagulation alone for intermediate-high risk pulmonary embolism.Frontiers in cardiovascular medicine · 2026Article
- Intermediate-Risk Pulmonary Embolism: Patients' Stratification, Prognosis, and Therapeutic Options-Time to Pay Attention to the Middle Child.Journal of clinical medicine · 2025Review
- Breaking embolic ground: the clot thickens in intermediate-risk pulmonary embolism.European heart journal open · 2025Article
- From Algorithms to Biomarkers: Toward Personalized Management of Venous Thromboembolism.Journal of clinical medicine · 2025Article
- Advancements in Acute Pulmonary Embolism Diagnosis and Treatment: A Narrative Review of Emerging Imaging Techniques and Intravascular Interventions.Journal of cardiovascular development and disease · 2025Review
- A Practical Clinical Approach to Navigate Pulmonary Embolism Management: A Primer and Narrative Review of the Evolving Landscape.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe optimal management of patients with intermediate-risk pulmonary embolism (PE), who have right heart dysfunction (determined by a combination of imaging and cardiac biomarkers) but a normal blood pressure, is uncertain. These patients suffer from reduced functional capacity and a lower quality of life over the long-term, despite use of anticoagulant therapy. Catheter-directed therapy (CDT) is a promising treatment for acute PE that rapidly removes thrombus and potentially improves cardiac dysfunction. However, CDT has risk and is costly, and it is not known whether it improves long-term cardiorespiratory fitness and/or quality of life compared with anticoagulation alone.
methodsWe are therefore conducting an open-label, assessor-blinded, multicenter randomized trial, the Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy (PE-TRACT) Study, to compare CDT plus anticoagulation (CDT group) with anticoagulation alone (No-CDT group) in 500 patients with intermediate-risk PE. The primary study hypothesis is that CDT will increase the peak oxygen uptake (peak VO
conclusionWhen completed, PE-TRACT will provide important evidence regarding the benefits and risks of CDT to treat intermediate-risk PE compared with anticoagulation alone.
trial registrationclinicaltrials.gov: NCT05591118.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.